NEW YORK, May 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Epidemiology: Insomnia
http://www.reportlinker.com/p0491920/Epidemiology-Insomnia.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Introduction
In this analysis, Datamonitor estimates that there were a total of 53 million cases of insomnia in 2010 in the seven major markets with nearly a half of these cases present in the US. Prevalence rates for insomnia are expected to remain constant; therefore, any changes in prevalence will depend on population dynamics in the seven major healthcare markets
Features and benefits
* Gain insight to market potential, including a robust 10-year epidemiology forecast of prevalent insomnia cases.
* Understand the key epidemiologic risk factors associated with insomnia.
Highlights
Datamonitor expects an increase in prevalent insomnia cases in the next decade in the seven major markets as a result of an ageing population.
Unsatisfactory sleep can cause severe distress and cause social, interpersonal, and occupational impairment.
Your key questions answered
* What are the most robust epidemiologic studies for insomnia prevalence data?
* How will the patient population change over the next decade in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK)?
* How do changes in population structure and risk factors affect the trend in prevalent insomnia cases?
Executive Summary
Strategic scoping and focus
Datamonitor key findings
Related reports
OVERVIEW
Catalyst
Summary
CLINICAL PIPELINE OVERVIEW
Overview of the depression pipeline
Datamonitor has identified 46 separate programs in clinical development
Emerging features of the depression pipeline
Changes in pipeline dynamics
Companies involved in the depression pipeline
Late-stage development compounds recently discontinued
TARGET PRODUCT PROFILE
Comparator therapies
Lexapro (escitalopram; Forest/Lundbeck)
Target product profile versus current level of attainment
CLINICAL TRIAL DESIGN IN DEPRESSION
Clinical trials
Commonly used clinical trial endpoints for depression
Typical trial design
Trial length is commonly standardized to a duration of just 8 weeks
Comparator trials can provide a compelling argument for using one drug ahead of another
Future developments in clinical trial design
Treatment-resistant depression clinical trial design
Adjunctive therapy clinical trial design
INNOVATIVE EARLY-STAGE APPROACHES
Glutamate receptor modulation
NMDA receptor antagonists and partial agonists
Metabotropic glutamate receptor antagonists
Targeting neuropeptides for depression
Background
Vasopressin receptor antagonists
Corticotropin-releasing factor receptor antagonists
Neurokinin receptor antagonists
THE FUTURE OF TREATMENT IN DEPRESSION
Specific targeting of treatment-resistant patients
A label for treatment-resistant depression will bypass competition with generic first-line antidepressants
Treatment-resistant depression is characterized by a large target population and substantial unmet need
Biomarkers for depression
Considerable variations in treatment outcomes exist
Biomarkers may have utility in identifying appropriate patients and improving treatment outcomes
The commercial appeal of reduced R&D spend and a competitive advantage is a bonus
Biomarkers in clinical development
BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
APPENDIX
Contributing experts
Conferences attended
Report methodology
To order this report:
Pathology Industry: Epidemiology: Insomnia
Pathology Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
Advertisement
Epidemiology: Insomnia
http://www.reportlinker.com/p0491920/Epidemiology-Insomnia.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Advertisement
Introduction
In this analysis, Datamonitor estimates that there were a total of 53 million cases of insomnia in 2010 in the seven major markets with nearly a half of these cases present in the US. Prevalence rates for insomnia are expected to remain constant; therefore, any changes in prevalence will depend on population dynamics in the seven major healthcare markets
Features and benefits
* Gain insight to market potential, including a robust 10-year epidemiology forecast of prevalent insomnia cases.
* Understand the key epidemiologic risk factors associated with insomnia.
Highlights
Datamonitor expects an increase in prevalent insomnia cases in the next decade in the seven major markets as a result of an ageing population.
Unsatisfactory sleep can cause severe distress and cause social, interpersonal, and occupational impairment.
Your key questions answered
* What are the most robust epidemiologic studies for insomnia prevalence data?
* How will the patient population change over the next decade in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK)?
* How do changes in population structure and risk factors affect the trend in prevalent insomnia cases?
Executive Summary
Strategic scoping and focus
Datamonitor key findings
Related reports
OVERVIEW
Catalyst
Summary
CLINICAL PIPELINE OVERVIEW
Overview of the depression pipeline
Datamonitor has identified 46 separate programs in clinical development
Emerging features of the depression pipeline
Changes in pipeline dynamics
Companies involved in the depression pipeline
Late-stage development compounds recently discontinued
TARGET PRODUCT PROFILE
Comparator therapies
Lexapro (escitalopram; Forest/Lundbeck)
Target product profile versus current level of attainment
CLINICAL TRIAL DESIGN IN DEPRESSION
Clinical trials
Commonly used clinical trial endpoints for depression
Typical trial design
Trial length is commonly standardized to a duration of just 8 weeks
Comparator trials can provide a compelling argument for using one drug ahead of another
Future developments in clinical trial design
Treatment-resistant depression clinical trial design
Adjunctive therapy clinical trial design
INNOVATIVE EARLY-STAGE APPROACHES
Glutamate receptor modulation
NMDA receptor antagonists and partial agonists
Metabotropic glutamate receptor antagonists
Targeting neuropeptides for depression
Background
Vasopressin receptor antagonists
Corticotropin-releasing factor receptor antagonists
Neurokinin receptor antagonists
THE FUTURE OF TREATMENT IN DEPRESSION
Specific targeting of treatment-resistant patients
A label for treatment-resistant depression will bypass competition with generic first-line antidepressants
Treatment-resistant depression is characterized by a large target population and substantial unmet need
Biomarkers for depression
Considerable variations in treatment outcomes exist
Biomarkers may have utility in identifying appropriate patients and improving treatment outcomes
The commercial appeal of reduced R&D spend and a competitive advantage is a bonus
Biomarkers in clinical development
BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
APPENDIX
Contributing experts
Conferences attended
Report methodology
To order this report:
Pathology Industry: Epidemiology: Insomnia
Pathology Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
